Chris de Graaf performed his PhD research in the Division Molecular Toxicology at VU University Amsterdam on computational ligand binding mode and affinity predictions in cytochrome P450 enzymes (2002-2006, cum laude). He then joined the Structural Chemogenomics group (Dr. Rognan) at Université de Strasbourg as post-doctoral fellow and worked in collaboration with AstraZeneca Pharmaceuticals on the development and application of novel G protein-coupled receptor modeling techniques (2006-2008). In 2009 Chris de Graaf was appointed assistant professor in the Division Medicinal Chemistry at VU University Amsterdam. In this interdisciplinary research environment Dr. De Graaf and his team have developed several in silico modeling methods that steer synthetic medicinal chemistry and molecular pharmacology programs. Dr. De Graaf has recently been appointed vice chair of the COST Action CM1207 GLISTEN to oversee the planning, implementation and coordination of this European G Protein-Coupled Receptor research network.